NP49425 Generic and Biosimilar Transition Medicines
Estimated value
£131.2m
Awarded value
—
Suppliers
0
Lots
9
Published
05 Aug 2025
This is a preliminary market engagement notice
Map the supplier landscape and document your shortlist before opening the tender. The market simulation produces a defensible audit record you can attach to your procurement file.
Description
The Authority seeks to establish a Framework Agreement covering medicines that are imminently approaching or have already reached Loss of Exclusivity (LoE). The range of medicines under consideration for inclusion in the Framework Agreement are listed below (subject to removal or replacement due to a continually shifting litigation landscape): - Apremilast 30mg tablets - Axitinib 1mg tablets - Axitinib 3mg tablets - Axitinib 5mg tablets - Axitinib 7mg tablets - Betaine oral powder - Denosumab 120mg/1.7ml solution for injection vials - Denosumab 120mg/1ml solution for injection pre-filled syringes - Denosumab 60mg/1ml solution for injection pre-filled syringes - Eltrombopag 25mg oral powder sachets sugar free - Eltrombopag 25mg tablets - Eltrombopag 50mg tablets - Eltrombopag 75mg tablets - Ferric carboxymaltose 100mg/2ml dispersion for injection vials - Ferric carboxymaltose 1g/20ml dispersion for injection vials - Ferric carboxymaltose 500mg/10ml dispersion for injection vials - Fluticasone furoate 27.5micrograms/dose nasal spray - Fluticasone propionate 50micrograms/dose / Azelastine 137micrograms/dose nasal spray - Generic Otezla tablets treatment initiation pack - Generic Sustanon 250mg/1ml solution for injection ampoules - Golimumab 100mg/1ml solution for injection pre-filled disposable devices - Golimumab 50mg/0.5ml solution for injection pre-filled disposable devices - Golimumab 50mg/0.5ml solution for injection pre-filled syringes - Lanreotide 120mg/0.5ml solution for injection pre-filled syringes - Lanreotide 90mg/0.5ml solution for injection pre-filled syringes - Lanreotide 60mg/0.5ml solution for injection pre-filled syringes - Mesalazine 1.5g gastro-resistant modified-release granules sachets sugar free - Mesalazine 1.6g gastro-resistant tablets - Mesalazine 1g gastro-resistant modified-release granules sachets sugar free - Mesalazine 1g modified-release granules sachets sugar free - Mesalazine 1g modified-release tablets - Mesalazine 1g suppositories - Mesalazine 1g/100ml enema - Mesalazine 1g/application foam enema - Mesalazine 250mg gastro-resistant tablets - Mesalazine 2g modified-release granules sachets sugar free - Mesalazine 2g/59ml enema - Mesalazine 400mg gastro-resistant tablets - Mesalazine 4g modified-release granules sachets sugar free - Mesalazine 500mg gastro-resistant modified-release granules sachets sugar free - Mesalazine 500mg gastro-resistant tablets - Mesalazine 500mg suppositories - Mesalazine 800mg gastro-resistant tablets - Nilotinib 150mg capsules - Nilotinib 200mg capsules - Nilotinib 50mg capsules - Nintedanib 100mg capsules - Nintedanib 150mg capsules - Omalizumab 150mg/1ml solution for injection pre-filled syringes - Omalizumab 75mg/0.5ml solution for injection pre-filled syringes - Omalizumab 300mg/2ml solution for injection pre-filled disposable devices - Omalizumab 300mg/2ml solution for injection pre-filled syringes - Pazopanib 200mg tablets - Pazopanib 400mg tablets - Perampanel 10mg tablets - Perampanel 12mg tablets - Perampanel 2mg tablets - Perampanel 4mg tablets - Perampanel 500micrograms/ml oral suspension sugar free - Perampanel 6mg tablets - Perampanel 8mg tablets - Pertuzumab 420mg/14ml solution for infusion vials 1 vial - Testosterone undecanoate 1g/4ml solution for injection ampoules - Testosterone undecanoate 1g/4ml solution for injection vials - Ticagrelor 60mg tablets - Ticagrelor 90mg orodispersible tablets sugar free - Ticagrelor 90mg tablets - Tocilizumab 162mg/0.9ml solution for injection pre-filled disposable devices - Tocilizumab 162mg/0.9ml solution for injection pre-filled syringes - Tocilizumab 200mg/10ml solution for infusion vials - Tocilizumab 400mg/20ml solution for infusion vials - Tocilizumab 80mg/4ml solution for infusion vials - Trabectedin 1mg powder for solution for infusion vials - Trabectedin 250microgram powder for solution for infusion vials
Scope
- Reference
- ocds-h6vhtk-0581ea
- Total value
- £131,244,104 excluding VAT
- Commercial tool
- Standalone contract
- Contract dates
- 01 Feb 2026 to 30 May 2028
The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty-six (36) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.
- Main category
- goods
- CPV classifications
- 33600000
- Contract locations
- Scotland
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Supply Chain | 5 | quality | — |
| — | 95 | price | — |
Lots · 9 total
Divisions of the contract. Each lot can be awarded separately.
| Lot | Title | Est. value | Status |
|---|---|---|---|
| 8 | Cancer Medicines (Group 2) | £15.2m | planned |
| 1 | Cytokine Modulators | £100.0m | planned |
| 2 | Gastrointestinal, Endocrine, Nutrition, Blood, and Multiple Sclerosis Medicines | £15.6m | planned |
| 3 | Denosumab (osteoporosis) | £26.2m | planned |
| 4 | Apremilast | £27.4m | planned |